SLC5A2 and hydrops fetalis: On the contrary, in patients with cardiac dysfunction, the serum levels of adropin increased significantly according to the New York Heart Association (NYHA) class of HF and demonstrated a tendency to decrease during treatment with hydralazine combined with sodium nitroprusside and SGLT2 inhibitors [27,29,30,31].